Previous Article | Next Article 
Antimicrobial Agents and Chemotherapy, May 2005, p. 1994-2001, Vol. 49, No. 5
0066-4804/05/$08.00+0 doi:10.1128/AAC.49.5.1994-2001.2005
Copyright © 2005, American Society for Microbiology. All Rights Reserved.
Mechanism of Anti-Human Immunodeficiency Virus Activity of ß-D-6-Cyclopropylamino-2',3'-Didehydro-2',3'-Dideoxyguanosine
Adrian S. Ray,1 Brenda I. Hernandez-Santiago,2 Judy S. Mathew,2 Eisuke Murakami,1 Carey Bozeman,2 Meng-Yu Xie,2 Ginger E. Dutschman,1 Elizabeth Gullen,1 Zhenjun Yang,3 Selwyn Hurwitz,2 Yung-Chi Cheng,1 Chung K. Chu,3 Harold McClure,4 Raymond F. Schinazi,2 and Karen S. Anderson1*Department of Pharmacology, Yale University School of Medicine, New Haven Connecticut 06520-8066,1 Laboratory of Biochemical Pharmacology, Department of Pediatrics, Emory University School of Medicine/VAMC, Decatur, Georgia 30033,2 Department of Pharmacology and Biomedical Sciences, College of Pharmacy, The University of Georgia, Athens, Georgia 30602-2352,3 Yerkes National Primate Research Center, Emory University, Atlanta, Georgia 303224
Received 2 July 2004/ Returned for modification 7 October 2004/ Accepted 5 January 2005
To better understand the importance of the oxygen in the ribose ring of planar unsaturated nucleoside analogs that target human immunodeficiency virus (HIV), a 6-cyclopropyl-substituted prodrug of 2',3'-didehydro-2',3'-dideoxyguanosine (cyclo-d4G) was synthesized, and its cellular metabolism, antiviral activity, and pharmacokinetic behavior were studied. Cyclo-d4G had selective anti-HIV activity in primary blood mononuclear cells (PBMCs), effectively inhibiting the LAI strain of HIV-1 by 50% at 1.1 ± 0.1 µM while showing 50% inhibition of cell viability at 84.5 µM. The antiviral activity in PBMCs was not markedly affected by mutations of methionine to valine at position 184 or by thymidine-associated mutations in the viral reverse transcriptase. Mutations of leucine 74 to valine and of lysine 65 to arginine had mild to moderate resistance (as high as fivefold). Studies to delineate the mechanism of cellular metabolism and activation of cyclo-d4G showed reduced potency in inhibiting viral replication in the presence of the adenosine/adenylate deaminase inhibitor 2'-deoxycoformycin, implying that the antiviral activity is due to its metabolism to the 2'-dGTP analog d4GTP. Intracellular formation of sugar catabolites illustrates the chemical and potentially enzymatic instability of the glycosidic linkage in d4G. Further studies suggest that cyclo-d4G has a novel intracellular phosphorylation pathway. Cyclo-d4G had a lower potential to cause mitochondrial toxicity than 2',3'-dideoxycytidine and 2',3'-didehydro-3'-deoxythymidine in neuronal cells. Also, cyclo-d4G had advantageous synergism with many currently used anti-HIV drugs. Poor oral bioavailability observed in rhesus monkeys may be due to the labile glycosidic bond, and special formulation may be necessary for oral delivery.
* Corresponding author. Mailing address: Department of Pharmacology, Yale School of Medicine, 333 Cedar St., P.O. Box 208066, New Haven, CT 06520-8066. Phone: (203) 785-4526. Fax: (203) 785-7670. E-mail: karen.anderson{at}yale.edu.
Antimicrobial Agents and Chemotherapy, May 2005, p. 1994-2001, Vol. 49, No. 5
0066-4804/05/$08.00+0 doi:10.1128/AAC.49.5.1994-2001.2005
Copyright © 2005, American Society for Microbiology. All Rights Reserved.
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»